698.MU

Healthcare Biotechnology

Achilles Therapeutics plc

€1.36

today

Price History

Not enough data

Key Stats

Market Cap

57.92M

Avg Volume

EPS

-€1.53

52W High

€1.36

Div. Yield

0.0%

Valuation

P/B Ratio

0.61

EV/EBITDA

0.42

Margins

Gross Margin 0.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(52.1%)

Return on Assets

(30.2%)

Liquidity & Leverage

Current Ratio

6.04

Quick Ratio

5.84

Debt / Equity

0.04

Total Cash

86.05M

Total Debt

3.62M

About

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.